ArticleTanaffos2024
Clinical Symptoms and Echocardiographic Markers Regarding the Severity of Embolism in Patients with Acute Pulmonary Embolism.
Article in Tanaffos, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ABO Blood Group and Biomarker-Based Risk in Acute Pulmonary Embolism: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Echocardiography can be used for risk stratification in patients with acute pulmonary embolism (PE). While the severity of PE has been assessed through laboratory criteria in most studies, the Pulmonary Embolism Severity Index (PESI) scoring system was used in this study to evaluate the severity of echocardiographic criteria in acute PE patients. Materials and Methods: All PE patients admitted to Ghaem Hospital in Mashhad between 2021-2022 were included in the study. Clinical symptoms and echocardiographic markers were checked and recorded when the patients entered the study. Data were analyzed in SPSS version 24 at a significance level of 0.05 using the Chi-square test and t-test. Results: Of 40 patients, 80% were at a high risk of PESI. The most common clinical symptoms were dyspnea (97.5%) and pleuritic chest pain (75%). Right ventricle (RV) size enlargement and its dysfunction were recorded in 57.5% of patients. The average age of patients in the high-risk group was significantly (pvalue: 0.001) higher than the low-risk group. There was a significant correlation between MID-right ventricle and pulmonary artery pressure with the severity of embolism, so that mid-right ventricle and pulmonary artery pressure in the high-risk group were significantly higher (p-value: 0.000) than in the low-risk group. Also, the severity of PE was significantly related to RV size (P = 0.026) and function (P = 0.038). Conclusion: RV size, function, and dilatation, and pulmonary artery pressure variated significantly in different severities of PE.
Indexed as
Identifiers
41018926PMC12464831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.